PFE and ARVN Related Headlines
Go Back- Arvinas Inc. (ARVN) PT Raised to $16 at BofA Securities
- Arvinas and Pfizer sell VEPPANU rights to Rigel for $85 million upfront
- Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
- Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
- FDA approves first PROTAC therapy VEPPANU for breast cancer
- Quanterix names Everett Cunningham as new president and CEO
- Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026
- Arvinas to present vepdegestrant data at breast cancer symposium
- Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)
- Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with
- Arvinas and Pfizer to out-license vepdegestrant commercialization rights
- Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation
- FDA accepts Arvinas drug application for advanced breast cancer treatment
- Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
PFE and ARVN Related Press Releases
Go Back- Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
- Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
- Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026
- Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)
- Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with
- Arvinas Provides Update on Collaboration with Pfizer and Announces Further Actions to Support Value Creation
- Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
